Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals.
Jameel AbdulrehmanSahar ZarabiCarolyne ElbazKerstin de WitYulia LinMichelle SholzbergRita SelbyPublished in: Research and practice in thrombosis and haemostasis (2021)
Compared with clinical trial data, we found a numerically higher rate of mortality and similar rate of ATE and VTE among patients treated with idarucizumab in the real world.